REUTERS.COM
cancer

Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug

SUMMARY

Pfizer has signed a $6 billion licensing agreement with 3SBio Inc to develop a drug aimed at treating certain cancers. The drug candidate is being tested for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors in China.

3SBio plans to start a Phase III trial this year, and the drug has received FDA clearance for its Investigational New Drug application.

The agreement grants Pfizer a global license, excluding China, for the drug SSGJ-707, with a potential option for commercialization rights in China.

Pfizer will manufacture the drug in North Carolina and Kansas and plans a $100 million equity investment in 3SBio.


▶︎ Click here for more breaking news